An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
Multiple Myeloma
DRUG: BIBF 1120 ES
Maximum tolerated dose (MTD), Up to 11 months
Incidence and intensity of adverse events according to Common Toxicity Criteria (CTC) associated with increasing doses of BIBF 1120, Up to 11 months|Change from baseline in laboratory parameters, Baseline, up to 11 months|Objective tumor response in surrogate markers, Baseline, up to 11 month|Concentration at 2h (C2,1), 2 hours after first administration|Change from baseline in cellular protein tyrosine kinase inhibition, Baseline, up to 11 months|Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance score, Baseline, up to 11 months|Change in vital signs, up to 11 months|Change from baseline in electrocardiogram (ECG), Baseline, up to 11 months|Predose concentration immediately before administration of the Nth dose over the dosing interval τ (Cpre,N), Up to day 28|Area under the plasma concentration-time curve during the dosing interval τ (24 h) at steady state (AUCτ,ss), Up to 11 months|Plasma concentration at the time point immediately before dosing at steady state (Cpre,ss), Up to 11 months|Minimum plasma concentration during the dosing interval τ at steady state (Cmin,ss), Up to 11 months|Maximum plasma concentration during the dosing interval τ at steady state (Cmax,ss), Up to 11 months|Time to reach minimum plasma concentration during the dosing interval τ at steady state (tmin,ss), Up to 11 months|Time to reach maximum plasma concentration during the dosing interval τ at steady state (tmax,ss), Up to 11 months|Terminal half-life at steady state (t1/2,ss), Up to 11 months|Apparent plasma clearance at steady state (CL/F,ss), Up to 11 months|Mean residence time at steady state (MRTpo,ss), Up to 11 months|Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss), Up to 11 months|Tumor response assessed according to the European Group for Blood and Marrow Transplantation (EBMT) criteria, Up to 11 months
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics